123 related articles for article (PubMed ID: 9219077)
1. Paroxetine in depressed adolescents with intellectual disability: an open label study.
Masi G; Marcheschi M; Pfanner P
J Intellect Disabil Res; 1997 Jun; 41 ( Pt 3)():268-72. PubMed ID: 9219077
[TBL] [Abstract][Full Text] [Related]
2. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
3. Paroxetine in the treatment of depressed patients with haematological malignancy: an open-label study.
Pae CU; Kim YJ; Won WY; Kim HJ; Lee S; Lee CU; Lee SJ; Kim DW; Lee C; Min WS; Kim CC; Paik IH; Serretti A
Hum Psychopharmacol; 2004 Jan; 19(1):25-9. PubMed ID: 14716708
[TBL] [Abstract][Full Text] [Related]
4. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.
Boulenger JP; Huusom AK; Florea I; Baekdal T; Sarchiapone M
Curr Med Res Opin; 2006 Jul; 22(7):1331-41. PubMed ID: 16834832
[TBL] [Abstract][Full Text] [Related]
5. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation.
Blier P; Gobbi G; Turcotte JE; de Montigny C; Boucher N; Hébert C; Debonnel G
Eur Neuropsychopharmacol; 2009 Jul; 19(7):457-65. PubMed ID: 19345072
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Hypericum extract WS 5570 and paroxetine in ongoing treatment after recovery from an episode of moderate to severe depression: results from a randomized multicenter study.
Anghelescu IG; Kohnen R; Szegedi A; Klement S; Kieser M
Pharmacopsychiatry; 2006 Nov; 39(6):213-9. PubMed ID: 17124643
[TBL] [Abstract][Full Text] [Related]
7. A double-blind study comparing paroxetine and maprotiline in depressed outpatients.
Szegedi A; Wetzel H; Angersbach D; Dunbar GC; Schwarze H; Philipp M; Benkert O
Pharmacopsychiatry; 1997 May; 30(3):97-105. PubMed ID: 9211571
[TBL] [Abstract][Full Text] [Related]
8. [A double-blind comparative study of the effectiveness and tolerance of paroxetine and amitriptyline in treatment of breast cancer patients with clinically assessed depression].
Möslinger-Gehmayr R; Zaninelli R; Contu A; Oberhoff C; Gutschow K; Schindler AE; Staab HJ
Zentralbl Gynakol; 2000; 122(4):195-202. PubMed ID: 10795116
[TBL] [Abstract][Full Text] [Related]
9. [Comparative study of paroxetine and mianserin in depression in elderly patients: efficacy, tolerance, serotonin dependence].
Daléry J; Aubin V
Encephale; 2001; 27(1):71-81. PubMed ID: 11294041
[TBL] [Abstract][Full Text] [Related]
10. A multicenter double-blind trial of paroxetine versus amitriptyline in depressed inpatients.
Stuppaeck CH; Geretsegger C; Whitworth AB; Schubert H; Platz T; König P; Hinterhuber H; Fleischhacker WW
J Clin Psychopharmacol; 1994 Aug; 14(4):241-6. PubMed ID: 7962679
[TBL] [Abstract][Full Text] [Related]
11. The treatment of depression with paroxetine in psychiatric practice in Germany: the possibilities and current limitations of drug monitoring.
Zaninelli R; Meister W
Pharmacopsychiatry; 1997 Jan; 30(1 Suppl):9-20. PubMed ID: 9035223
[TBL] [Abstract][Full Text] [Related]
12. The influence of educational information on depressed outpatients treated with escitalopram: a semi-naturalistic study.
Leinonen E; Niemi H
Nord J Psychiatry; 2007; 61(2):109-14. PubMed ID: 17454725
[TBL] [Abstract][Full Text] [Related]
13. Effective dose of escitalopram in moderate versus severe DSM-IV major depression.
Bech P; Andersen HF; Wade A
Pharmacopsychiatry; 2006 Jul; 39(4):128-34. PubMed ID: 16871468
[TBL] [Abstract][Full Text] [Related]
14. Superiority of escitalopram to paroxetine in the treatment of depression.
Kasper S; Baldwin DS; Larsson Lönn S; Boulenger JP
Eur Neuropsychopharmacol; 2009 Apr; 19(4):229-37. PubMed ID: 19185467
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of paroxetine for the treatment of depression in the context of HIV infection.
Grassi B; Gambini O; Garghentini G; Lazzarin A; Scarone S
Pharmacopsychiatry; 1997 Mar; 30(2):70-1. PubMed ID: 9131727
[TBL] [Abstract][Full Text] [Related]
16. Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil.
Lee P; Shu L; Xu X; Wang CY; Lee MS; Liu CY; Hong JP; Ruschel S; Raskin J; Colman SA; Harrison GA
Psychiatry Clin Neurosci; 2007 Jun; 61(3):295-307. PubMed ID: 17472599
[TBL] [Abstract][Full Text] [Related]
17. Clinical application of paroxetine for tapering benzodiazepine use in non-major-depressive outpatients visiting an internal medicine clinic.
Nakao M; Takeuchi T; Nomura K; Teramoto T; Yano E
Psychiatry Clin Neurosci; 2006 Oct; 60(5):605-10. PubMed ID: 16958945
[TBL] [Abstract][Full Text] [Related]
18. The onset of effect for escitalopram and its relevance for the clinical management of depression.
Wade A; Friis Andersen H
Curr Med Res Opin; 2006 Nov; 22(11):2101-10. PubMed ID: 17076970
[TBL] [Abstract][Full Text] [Related]
19. Time course of response to paroxetine: influence of plasma level.
Gex-Fabry M; Gervasoni N; Eap CB; Aubry JM; Bondolfi G; Bertschy G
Prog Neuropsychopharmacol Biol Psychiatry; 2007 May; 31(4):892-900. PubMed ID: 17395353
[TBL] [Abstract][Full Text] [Related]
20. [Paroxetine in the treatment of depressive disorders (pilot study)].
Svestka J; Novotný V; Kamenická V; Obrovská V; Cesková E
Cesk Psychiatr; 1995 Jul; 91(3):135-42. PubMed ID: 7553946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
